Additive effects of CD59 expression in Gal knockout mice in vitro but not in an ex vivo model

Xenotransplantation

Volumn 4, Issue 1, 1997, Pages 25-33

  Tange, Margaret J ^a   Salvaris, Evelyn ^a   Romanella, Margarita ^a   Aminian, Atousa ^a   Katerelos, Marina ^a   Somerville, Christine ^a   Tearle, Rick G ^b   Pearse, Martin J ^a   D'Apice, Anthony J F ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b BresaGen Limited   (Australia)

Author keywords

CD59; Gal KO; Spleen cells

Indexed keywords

EID: 0002031241     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3089.1997.tb00161.x     Document Type: Article

References (28)

1. COOPER DKC, YE Y, ROLF LL, ZHUDI N. The pig as a potential organ donor for man. In: Xenotransplantation. COOPER DKC, REEMTSMA K, WHITE DJG, eds. Heidelberg; Springer Verlag, 1991:481.
2. GALILI U, MACHER BA, BUCHLER J, SHOHET SB. Human natural anti-α galactosyl IgG. II. The specific recognition of α(1,3) linked galactosyl residues. J Exp Med 1985:162:573.
3. GALILI U, SHOHET SB, KORBIN E, STULTS CLM, Macher BA. Man, apes and old world monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J Biol Chem 1988:263:17755.
4. SANDRIN MS, VAUGHAN HA, DABKOWSKI PL, MCKENZIE IFC. Anti-pig IgM antibodies in human serum react predominantly with Gal(α 1-3)Gal epitopes. Proc Natl Acad Sci USA 1993:90:11391.
5. COOPER DKC, GOOD AH, KOREN E, et al. Identification of α-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: Relevance to discordant xenografting in man. Transplant Immunol 1993:1:198.
6. Oriol R, Ye Y, Koren E, Cooper DKC. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation. Transplantation 1993:56:1433.
7. GALILI U, SWANSON K. Gene sequences suggest inactivation of α-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci USA 1991:88:7401.
8. GALILI U. Evolution and pathophysiology of the human natural anti-α-galactosyl IgG (anti-Gal) antibody. Springer Semin Immunopathol 1993:15:155.
9. GALILI U, MANDRELL RE, HAMEDEH RM, SHOHET SB, GRIFFITHS JMcL. Interaction between natrual anti-α-galactosyl immunoglobulin G and bacterial of the human flora. Immun Infect 1988:56:1630.
10. YE Y, NEETHLING FA, NIEKRASZ M, et al. Evidence that intravenously administered α-galactosyl carbohydrates reduce baboon serum cytotoxicity to pig kidney cells (PK 15) and transplanted pig hearts. Transplantation 1994:58:330.
11. COOPER DKC, KOREN E, ORIOL R. Manipulation of the anti-α Gal antibody-αGal epitope system in experimental discordant xenotransplantation. Xenotransplantation 1996:3:102.
12. TEARLE RG, TANGE MJ, ZANNETTINO ZL, et al. The α-1,3-galactosyltransferase knockout mouse: Implications for xenotransplantation. Transplantation 1996:61:13.
13. CHEN C-G, FISICARO N, SHINKEL TA, et al. Reduction in Gal-α1,3-Gal epitope expression in transgenic mice expressing human H-transferase. Xenotransplantation 1996:3:69.
14. SANDRIN MS, FODOR WL, COHNEY S, et al. Reduction of the major porcine xenoantigen Gal α (1,3)Gal by expression of α (1,2)fucosyltransferase. Xenotransplantation 1996:3:134.
15. KOIKE C, KANNAGI R, TAKUMA Y, et al. Introduction of α (1,2)-fucosyltransferase and its effect on α-Gal epitopes in transgenic pig. Xenotransplantation 1996:3:81.
16. LACHMANN PJ. The control of homologous lysis. Immunol Today 1991:12:312.
17. BALDWIN WM, PRUITT SK, BRAUER RB, DAHA MR, SANFILIPPO F. Complement in organ transplantation: Contributions to inflammation, injury and rejection. Transplantation 1995:59:797.
18. SOMERVILLE CA, KYRIAZIS AG, MCKENZIE AM, ALLISON J, PEARSE MJ, D'APICE AJF. Functional expression of human CD59 in transgenic mice. Transplantation 1994:58:1430.
19. PANACCIO M, GEORGESZ M, LEW AM. FoLT PCR: a simple PCR protocol for amplifying DNA directly from whole blood. BioTechniques 1993:14:238.
20. STEFANOVA I, HILGERT I, KRISTOFOVA H, BROWN R, LOW MG, HOREJSKI V. Characterisation of a broadly expressed human leukocyte surface antigen MEM43 anchored in the membrane through phosphatidyl-inositol. Mol Immunol 1989:26:153.
21. PAPADOPOULOS NG, DEDOUSSIS GVZ, SPANAOKOS G, GRITZAPIS AD, BAXEVANIS CN, PAPAMICHAIL M. An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. J Immunol Methods 1994:177:101.
22. HARRISON RA, LACHMANN PJ. Complement Technology. In: Handbook of Experiment Immunology Part I, Immunochemistry. Weir D, Herzenberg L, Blackwell C, eds. London: Blackwell Scientific Publications, 1986:1.
23. GRUPP IL, SUBRAMANIAM A, HEWETT TE, ROBBINS J, GRUPP G, Comparison of normal, hypodynamic, and hyperdynamic mouse hearts using isolated work-performing heart preparations. Am J Physiol 1993:265:H1401.
24. DIAMOND LE, MCCURRY KR, MARTIN MJ, et al. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996:61:1241.
25. MORGAN BP, IMAGAWA DK, DANKERT JR, RAMM LE. Complement lysis of U937, a nucleated mammalian cell line in the absence of C9: Effect of C9 on C5b-8 mediated cell lysis. J Immunol 1986:136:3402.
26. SUTTORP N, SEEGER W, ZINSKY S, BHAKDI S. Complement complex C5b-8 induced PGI2 formation in cultured endothelial cells. Am J Physiol 1987:253:C13.
27. COWAN PJ, SHINKEL TA, WITORT EJ, et al. Targeting gene expression to endothelial cells in transgenic mice using human intercellular adhesion molecule 2 promoter. Transplantation 1996:62:155.
28. BROOIMANS RA, VANDERARK AAJ, TOMITA A, et al. CD59 expressed by human endothelial cells functions as a protective molecule against complement mediated lysis. Eur J Immunol 1992:22:791.